ES2746839T3 - Derivados de pirimidina y triazina y su uso como inhibidores de AXL - Google Patents

Derivados de pirimidina y triazina y su uso como inhibidores de AXL Download PDF

Info

Publication number
ES2746839T3
ES2746839T3 ES15812888T ES15812888T ES2746839T3 ES 2746839 T3 ES2746839 T3 ES 2746839T3 ES 15812888 T ES15812888 T ES 15812888T ES 15812888 T ES15812888 T ES 15812888T ES 2746839 T3 ES2746839 T3 ES 2746839T3
Authority
ES
Spain
Prior art keywords
alkyl
group
independently selected
cycloalkyl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15812888T
Other languages
English (en)
Inventor
Ted William Johnson
Paul Francis Richardson
Michael Raymond Collins
Daniel Tyler Richter
Benjamin Joseph Burke
Ketan Gajiwala
Sacha Ninkovic
Maria Angelica Linton
Phuong Thi Quy Le
Jacqui Elizabeth Hoffman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2746839T3 publication Critical patent/ES2746839T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Un compuesto de Fórmula (I):**Fórmula** en la que: cada uno de X es N o CR6, en el que al menos uno de X es N, en el que cada R6 se selecciona independientemente entre el grupo que consiste en hidrógeno, halógeno, alquilo (C1-C8), alquenilo (C2-C3), alquinilo (C1-C8), haloalquilo (C1-C8), -alquilen (C1-C4)-R7, -OR7, -CN, -NO2 y -NR7R7, en el que cada R7 se selecciona independientemente entre el grupo que consiste en hidrógeno y alquilo (C1-C8) y en el que cada uno de dicho alquilo (C1-C8) en R6 está opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente entre el grupo que consiste en halógeno, hidroxilo y alcoxi (C1-C8); Y es Y1-Y2 o Y2-Y1, en el que Y1 está ausente o es alquileno (C1-C8), y en el que Y2 está ausente o es oxígeno; Z es Z1-Z2, en el que cada uno de Z1 y Z2 está independientemente ausente o se selecciona entre el grupo que consiste en alquileno (C1-C8), alquenileno (C2-C8), cicloalquilo (C3-C10), heterociclilo de 3-12 miembros y heteroalquileno (C1-C8), en el que Z está de manera opcional independientemente sustituido con uno o más R10, en el que cada R10 se selecciona independientemente entre el grupo que consiste en halógeno, alquilo (C1-C8), - CN, =O, -OR11 y -NO2, y en el que cada R11 se selecciona independientemente entre el grupo que consiste en hidrógeno, alquilo (C1-C8), cicloalquilo (C3-C10), heterociclilo de 3-12 miembros, arilo (C6-C12) y heteroarilo de 5-12 miembros; cada R1 se selecciona independientemente entre el grupo que consiste en hidrógeno, halógeno, alquilo (C1-C8), haloalquilo (C1-C8), -(alquil C1-C4)R7, -OR7, -CN, -C(O)R7, -CO2R7, -C(O)NR7R7, -SR7, -SOR7, -SO2R7, -SO2NR7R7, -NO2, -NR7R7, -NR7C(O)R7, -NR7C(O)NR7R7, -NR7C(O)OR7, -NR7SO2R7, -NR7SO2NR7R7, -OC(O)R7 y - OC(O)NR7R7; en el que cualquier conjunto de dos R1 en los mismos o diferentes carbonos de piperidina se unen opcionalmente para formar un sistema de anillo espirocíclicos, condensados o puenteados que comprende de 1-4 miembros no de piperidina y de 1-2 heteroátomos seleccionados entre N, O y S, y en el que cualquier conjunto de dos R1 en los carbonos de piperidina adyacentes se unen opcionalmente para formar un enlace carbono-carbono; R2 y R3 cada uno de se selecciona independientemente entre el grupo que consiste en hidrógeno, alquilo (C1-C8), haloalquilo (C1-C8), cicloalquilo (C3-C10), heterociclilo de 3-12 miembros, -OR13 y -SO2R14, en el que cada R13 se selecciona independientemente entre el grupo que consiste en hidrógeno, alquilo (C1-C4) y haloalquilo (C1-C4), en el que cada R14 se selecciona independientemente entre el grupo que consiste en hidrógeno y alquilo (C1-C8) y en el que R2, R3 o ambos R2 y R3 está opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente entre halógeno, alquilo (C1-C8), hidroxilo, alcoxi (C1-C4), -CN, NH2, NH(alquilo C1-C4) y N(alquilo C1-C4)2; piperazinilo, piperadinonilo, piperazinonilo y morfolinilo, opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente entre el grupo que consiste en R15 y alquilen (C1-C4)-R15, en el que R15 se selecciona independientemente entre el grupo que consiste en halógeno, alquilo (C1-C4), haloalquilo (C1-C4), hidroxilo, alcoxi (C1-C4), CN, NH2, NH(alquilo C1-C4), N(alquilo C1-C4)2 y cicloalquilo (C3-C10); R4 se selecciona entre el grupo que consiste en alquilo (C1-C8), haloalquilo (C1-C8), cicloalquilo (C3-C10), heterociclilo de 3-12 miembros y -C(O)NR14R14, en el que R4 está opcionalmente sustituido con uno o más R12 independientemente seleccionados entre halógeno, hidroxilo, alcoxi (C1-C4), -CN, NH2, NH(alquilo C1-C4), N(alquilo C1-C4)2, cicloalquilo (C3-C10), heterociclilo de 3-12 miembros, arilo (C6-C12) y heteroarilo de 5-12 miembros, y en el que, cuando R12 es alcoxi (C1-C4), NH(alquilo C1-C4), N(alquilo C1-C4)2, cicloalquilo (C3-C10), heterociclilo de 3-12 miembros, arilo (C6-C12) o heteroarilo de 5-12 miembros, está opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente entre halógeno, hidroxilo, alcoxi (C1-C4), -CN, NH2, NH(alquilo C1-C4), N(alquilo C1-C4)2, cicloalquilo (C3-C10), heterociclilo de 3-12 miembros, arilo (C6-C12) y heteroarilo de 5-12 miembros; R5 es heteroarilo mono o bicíclico, opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente entre el grupo que consiste en alquilo (C1-C8), -OR13, -NR14R14,-C(O)NR14R14 y heteroarilo monocíclico, dicho uno o más sustituyentes opcionales están adicionalmente opcionalmente sustituidos con uno o más sustituyentes seleccionados del grupo que consiste en alquilo (C1-C8), alquilen (C1-C8)-OH, haloalquilo (C1- C8), cicloalquilo (C3-C10), heterociclilo de 3-12 miembros, -OR13, -NR14R14, -C(O)NR14R14, -SO2NR14R14, -SO2R14, -NR14SO2R14 y CN; y m es 1-9, o una sal farmacéuticamente aceptable del mismo.
ES15812888T 2014-12-18 2015-12-04 Derivados de pirimidina y triazina y su uso como inhibidores de AXL Active ES2746839T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462093844P 2014-12-18 2014-12-18
PCT/IB2015/059360 WO2016097918A1 (en) 2014-12-18 2015-12-04 Pyrimidine and triazine derivatives and their use as axl inhibitors

Publications (1)

Publication Number Publication Date
ES2746839T3 true ES2746839T3 (es) 2020-03-09

Family

ID=54851370

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15812888T Active ES2746839T3 (es) 2014-12-18 2015-12-04 Derivados de pirimidina y triazina y su uso como inhibidores de AXL

Country Status (6)

Country Link
US (1) US9593097B2 (es)
EP (1) EP3233829B1 (es)
JP (1) JP6621477B2 (es)
CA (1) CA2915356A1 (es)
ES (1) ES2746839T3 (es)
WO (1) WO2016097918A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016183071A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Hetero-tricyclic compounds and their use for the treatment of cancer
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
JP6885390B2 (ja) 2016-02-26 2021-06-16 小野薬品工業株式会社 Ａｘｌ阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬
UA123785C2 (uk) 2016-03-28 2021-06-02 Інсайт Корпорейшн Сполуки піролотриазину як інгібітори tam
RS62913B1 (sr) * 2016-09-09 2022-03-31 Novartis Ag Jedinjenja i sastavi kao inhibitori endozomskih toličnih receptora
US20200197385A1 (en) 2017-08-23 2020-06-25 Ono Pharmaceutical Co., Ltd. Therapeutic agent for cancer containing axl inhibitor as active ingredient
JP2020535168A (ja) 2017-09-27 2020-12-03 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｔａｍ阻害剤として有用なピロロトリアジン誘導体の塩
JP7223998B2 (ja) 2017-10-13 2023-02-17 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
GB201801355D0 (en) 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds
MA54133B1 (fr) 2018-03-08 2022-01-31 Incyte Corp Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y
EP3813800A1 (en) 2018-06-29 2021-05-05 Incyte Corporation Formulations of an axl/mer inhibitor
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
JP7458406B2 (ja) 2018-12-21 2024-03-29 セルジーン コーポレーション Ｒｉｐｋ２のチエノピリジン阻害剤
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR102286372B1 (ko) * 2019-05-27 2021-08-05 주식회사한국파마 Jak 저해제 화합물, 및 이를 포함하는 의약 조성물
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022220227A1 (ja) * 2021-04-14 2022-10-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 テトラヒドロピリドピリミジン化合物
CN113354638A (zh) * 2021-07-12 2021-09-07 天津敬康生物科技有限公司 一种5-氟-3-碘-1H-吡唑并[3,4-b]吡啶的制备方法
CN114853768A (zh) * 2022-07-08 2022-08-05 南昌大学 一种合成手性3-氟-1-氮杂二环[2,2,1]庚烷的方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
EP0755313B1 (en) 1994-04-12 1999-07-14 Porter Cable Corporation Toolless quickchange blade clamp for reciprocating saws
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
MX9708026A (es) 1995-04-20 1997-11-29 Pfizer Derivados del acido arislfulfonil hidroxamico, composiciones que los contienen y uso de los mismos.
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
EP0780386B1 (en) 1995-12-20 2002-10-02 F. Hoffmann-La Roche Ag Matrix metalloprotease inhibitors
PT885198E (pt) 1996-03-05 2002-06-28 Astrazeneca Ab Derivados de 4-anilinoquinazolina
EP0907649A1 (en) 1996-06-27 1999-04-14 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
EA199900021A1 (ru) 1996-07-13 1999-08-26 Глаксо, Груп Лимитед Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
EP0912559B1 (en) 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
EP0923585B1 (en) 1996-07-18 2002-05-08 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
EA199900139A1 (ru) 1996-08-23 1999-08-26 Пфайзер, Инк. Производные арилсульфониламиногидроксамовой кислоты
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
ATE272640T1 (de) 1997-01-06 2004-08-15 Pfizer Cyclische sulfonderivate
JP3765584B2 (ja) 1997-02-03 2006-04-12 ファイザー・プロダクツ・インク アリールスルホニルアミノヒドロキサム酸誘導体
BR9807824A (pt) 1997-02-07 2000-03-08 Pfizer Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz
IL131123A0 (en) 1997-02-11 2001-01-28 Pfizer Arylsulfonyl hydroxamic acid derivatives
CA2289102A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
JP2002501532A (ja) 1997-05-30 2002-01-15 メルク エンド カンパニー インコーポレーテッド 新規血管形成阻害薬
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
ATE263147T1 (de) 1997-08-08 2004-04-15 Pfizer Prod Inc Derivate von aryloxyarylsulfonylamino hydroxyaminsäuren
DE69838172T2 (de) 1997-08-22 2008-04-10 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
WO1999024440A1 (en) 1997-11-11 1999-05-20 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
JPH11236333A (ja) 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
CA2314156C (en) 1998-05-29 2010-05-25 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
DE69915004T2 (de) 1998-11-05 2004-09-09 Pfizer Products Inc., Groton 5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
EP1140179A2 (en) 1998-12-23 2001-10-10 G.D. SEARLE & CO. Use of a cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
GB9912961D0 (en) 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors
TW200526626A (en) * 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
WO2007056151A2 (en) * 2005-11-03 2007-05-18 Irm Llc Protein kinase inhbitors
US8877745B2 (en) * 2010-05-12 2014-11-04 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
US9672526B2 (en) 2012-03-13 2017-06-06 American Express Travel Related Services Company, Inc. Systems and methods for tailoring marketing
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys

Also Published As

Publication number Publication date
EP3233829B1 (en) 2019-08-14
US20160176850A1 (en) 2016-06-23
CA2915356A1 (en) 2016-06-18
US9593097B2 (en) 2017-03-14
EP3233829A1 (en) 2017-10-25
JP2017537951A (ja) 2017-12-21
WO2016097918A1 (en) 2016-06-23
JP6621477B2 (ja) 2019-12-18

Similar Documents

Publication Publication Date Title
ES2746839T3 (es) Derivados de pirimidina y triazina y su uso como inhibidores de AXL
CR20170118A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
CY1124514T1 (el) Ενωσεις [1,2,4]τριαζολο[1,5-α]πυριδινυλ-υποκατεστημενης ινδολης
CY1122127T1 (el) Νεες ενωσεις σπειρο[3η-ινδολο-3,2-πυρρολιδιν]-2(1η)-ονης και παραγωγα ως αναστολεις mdm2-p53
CY1123991T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1124284T1 (el) Ενωσεις σπειρο[3η-ινδολο-3,2'-πυρρολιδιν]-2(1η)-ονης και παραγωγα ως αναστολεις mdm2-p53
CL2016002942A1 (es) Nuevos derivados de pirazolina pirimidina y su uso como inhibidores de malt1
PH12017501825B1 (en) Bicyclic quinazolinone derivatives
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
PE20171306A1 (es) Derivados de quinazolina utilizados para tratar el vih
UY36734A (es) Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen
BR112014006660A2 (pt) novos derivados de dihidroquinolina-2-ona bicíclicos
CR20180363A (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen
CY1121677T1 (el) Ενωσεις διμεθυλοβενζοϊκου οξεος
CO6640226A2 (es) 5-fluoro-1h-pirazolipiridinas sustituidas y su uso
PE20181024A1 (es) Derivados de ciclohexano sustituido con amido
MX2016011992A (es) Derivados de piperidina-diona.
EA201600128A1 (ru) СОЛИ ПРОИЗВОДНЫХ 2-АМИНО-1-ГИДРОКСИЭТИЛ-8-ГИДРОКСИХИНОЛИН-2(1Н)-ОНА, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ И АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ
NI201700129A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa.
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
MX2015001099A (es) Nuevos derivados biciclicos de piridina.
UY31973A (es) Derivados de indol macrocíclicos útiles como inhibidores del virus de la hepatitis c
CO2017009353A2 (es) Derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd
TR201900680T4 (tr) CXCR3 Reseptör modülatörleri olarak hidroksialkil- piperazin türevleri.
TR201900659T4 (tr) Mineralokortikoid reseptör modülatörleri olarak benzoksazinon amidleri.